Tai Felicia, Mandelcorn Efrem D, Somani Sohel
Faculty of Medicine, University of Toronto, Canada.
Department of Ophthalmology & Vision Sciences, University of Toronto, Canada.
Am J Ophthalmol Case Rep. 2020 Oct 3;20:100943. doi: 10.1016/j.ajoc.2020.100943. eCollection 2020 Dec.
To report a case of neovascularization of posterior capsule (NVPC) successfully treated with intravitreal ranibizumab (Lucentis) and neodymium:YAG (Nd:YAG) capsulotomy, followed by phacogenic uveitis.
We report a systemically otherwise healthy 81-year-old male presenting with unilateral NVPC and iris (NVI) occurring five years after a central retinal vein occlusion. A single intravitreal injection of ranibizumab led to complete regression of NVPC and NVI within three weeks after which a Nd:YAG capsulotomy was performed. Two weeks later, the patient returned with a severe inflammatory reaction diagnosed as phacogenic uveitis and treated with surgical capsular bag/intraocular lens complex removal and peripheral pan-retinal photocoagulation. One-year follow-up demonstrated no recurrence of NVPC. Visual acuity remained at baseline of light perception.
We acknowledge that intravitreal anti-vascular endothelial growth factor treatment with Nd:YAG capsulotomy for NVPC is a rational option, but raise awareness to the rare possibility of phacogenic uveitis.
报告一例后囊膜新生血管化(NVPC)患者,经玻璃体内注射雷珠单抗(Lucentis)及钕:钇铝石榴石(Nd:YAG)晶状体囊切开术成功治疗,但随后发生了晶状体源性葡萄膜炎。
我们报告了一例81岁全身健康男性,在视网膜中央静脉阻塞五年后出现单侧NVPC及虹膜新生血管(NVI)。单次玻璃体内注射雷珠单抗导致NVPC和NVI在三周内完全消退,之后进行了Nd:YAG晶状体囊切开术。两周后,患者因严重炎症反应复诊,被诊断为晶状体源性葡萄膜炎,并接受了手术摘除晶状体囊袋/人工晶状体复合体及周边全视网膜光凝治疗。一年随访显示NVPC未复发。视力维持在光感的基线水平。
我们认可玻璃体内抗血管内皮生长因子治疗联合Nd:YAG晶状体囊切开术治疗NVPC是一种合理的选择,但需提高对晶状体源性葡萄膜炎这种罕见可能性的认识。